Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve T cell activation and effector differentiation. They are, likewise, involved in the induction and maintenance of immune tolerance in homeostatic conditions. Their phenotypic and functional heterogeneity points to their great plasticity and ability to modulate, according to their microenvironment, the acquired immune response and, at the same time, makes their precise classification complex and frequently subject to reviews and improvement. This review will present general aspects of the DC physiology and classification and will address their potential and actual uses in the management of human disease, more specifically cancer, as therapeutic and monitoring tools. New combination treatments with the participation of DC will be also discussed.

More information Original publication

DOI

10.3389/fimmu.2018.03176

Type

Journal article

Publication Date

2018-01-01T00:00:00+00:00

Volume

9

Keywords

DC, cancer combination therapies, cancer vaccines, human dendritic cells, mo-DC, monocyte-derived dendritic cells, Animals, Biomarkers, Cancer Vaccines, Cell Differentiation, Combined Modality Therapy, Dendritic Cells, Humans, Immune System, Immune System Phenomena, Immunotherapy, Neoplasms, Phenotype, Treatment Outcome, Tumor Microenvironment